Effect of curcumin on vascular endothelial growth factor expression in diabetic mice kidney induced by streptozotocin

Journal of the Medical Association of Thailand

Volumn 93, Issue SUPPL 2, 2010, Pages

  Sawatpanich, Tarinee ^a   Petpiboolthai, Hattaya ^a   Punyarachun, Busaba ^a   Anupunpisit, Vipavee ^a  

^a SRINAKHARINWIROT UNIVERSITY   (Thailand)

Author keywords

Curcumin; Immunohistochemistry; Streptozotocin; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CURCUMIN; STREPTOZOCIN; VASCULOTROPIN;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; METABOLISM; PATHOLOGY; RAT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CURCUMIN; DIABETES MELLITUS, EXPERIMENTAL; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; RATS; STREPTOZOCIN; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79952274286     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Liu E, Morimoto M, Kitajima S, Koike T, Yu Y, Shiiki H, et al. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol 2007; 18: 2094-104.
2. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-17.
3. De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 2001; 12: 993-1000.
4. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002; 51: 3090-4.
5. Grone HJ, Simon M, Grone EF. Expression of vascular endothelial growth factor in renal vascular disease and renal allografts. J Pathol 1995; 177: 259-67.
6. Shulman K, Rosen S, Tognazzi K, Manseau EJ, Brown LF. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 1996; 7: 661-6.
7. Kameswara RB, Appa RB. Hypoglycemic and antihyper-glycemic activity of Syzygium alternifolium (Wt.) Walp. seed extracts in normal and diabetic rats. Phytomedicine 2001; 8: 88-93.
8. Arun N, Nalini N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum Nutr 2002; 57: 41-52.
9. Suresh BP, Srinivasan K. Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozotocin diabetic rats. Mol Cell Biochem 1998; 181: 87-96.
10. Chen H, Zhang ZS, Zhang YL, Zhou DY. Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer Res 1999; 19: 3675-80.
11. Korutla L, Kumar R. Inhibitory effect of curcumin on epidermal growth factor receptor kinase activity in A431 cells. Biochim Biophys Acta 1994; 1224: 597-600.
12. Folkman J. Can mosaic tumor vessels facilitate molecular diagnosis of cancer? Proc Natl Acad Sci U S A 2001; 98: 398-400.
13. Arbiser JL, Klauber N, Rohan R, van Leeuwen R, Huang MT, Fisher C, et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 1998; 4: 376-83.
14. Cha DR, Kang YS, Han SY, Jee YH, Han KH, Han JY, et al. Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats. J Endocrinol 2004; 183: 183-94.
15. Sharma S, Kulkarni SK, Chopra K. Curcumin, the active principle of turmeric (Curcuma longa), ameliorates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 2006; 33: 940-5.
16. Okazaki M, Zhang H, Tsuji M, Morio Y, Oguchi K. Blood coagulability and fibrinolysis in streptozotocin-induced diabetic rats. J Atheroscler Thromb 1997; 4: 27-33.
17. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-17.
18. Osterby R, Gundersen HJ. Fast accumulation of basement membrane material and the rate of morphological changes in acute experimental diabetic glomerular hypertrophy. Diabetologia 1980; 18: 493-500.
19. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999; 42: 579-88.
20. Braun L, Kardon T, Reisz-Porszasz ZS, Banhegyi G, Mandl J. The regulation of the induction of vascular endothelial growth factor at the onset of diabetes in spontaneously diabetic rats. Life Sci 2001; 69: 2533-42.
21. Hoshi S, Shu Y, Yoshida F, Inagaki T, Sonoda J, Watanabe T, et al. Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats. Lab Invest 2002; 82: 25-35.
22. Cha DR, Kim NH, Yoon JW, Jo SK, Cho WY, Kim HK, et al. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl 2000; 77: S104-S112.
23. Yamamoto Y, Maeshima Y, Kitayama H, Kitamura S, Takazawa Y, Sugiyama H, et al. Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 2004; 53: 1831-40.
24. Yuan HT, Tipping PG, Li XZ, Long DA, Woolf AS. Angiopoietin correlates with glomerular capillary loss in anti-glomerular basement membrane glomerulonephritis. Kidney Int 2002; 61: 2078-89.
25. Aiello LP. Angiogenic pathways in diabetic retin opathy. N Engl J Med 2005; 353: 839-41.
26. Cho ML, Jung YO, Moon YM, Min SY, Yoon CH, Lee SH, et al. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett 2006; 103: 159-66.
27. Williams B, Gallacher B, Patel H, Orme C. Glucoseinduced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997; 46: 1497-503.
28. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, et al. Vascular endothelial growth factorinduced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46: 1473-80.
29. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728-31.
30. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, et al. Advanced glycation end product-induced apoptosis and overexpres-sion of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002; 277: 20309-15.
31. Tilton RG, Kawamura T, Chang KC, Ido Y, Bjercke RJ, Stephan CC, et al. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor. J Clin Invest 1997; 99: 2192-202.
32. Lehmann R, Schleicher ED. Molecular mechanism of diabetic nephropathy. Clin Chim Acta 2000; 297: 135-44.
33. Wilmer WA, Dixon CL, Hebert C. Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway. Kidney Int 2001; 60: 858-71.